Endoscopic Management of Nonvariceal Upper Gastrointestinal Bleeding: State of the Art

Muguruma, Naoki; Kitamura, Shinji; Kimura, Tooru; Miyamoto, Hiroshi; Takayama, Tetsuji

doi:10.5946/ce.2015.48.2.96

Cited by 8 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite recent technical advances in therapeutic endoscopy, acute nonvariceal upper gastrointestinal bleeding (NVUGIB) remains an important medical issue that is strongly associated with morbidity and mortality [ 1 2 ]. Tumors are a common cause of NVUGIB, and bleeding associated with gastric cancer reportedly accounts for approximately 1%–5% of cases of acute upper gastrointestinal bleeding (UGIB) [ 3 4 5 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Outcomes of Endoscopic Hemostasis for Bleeding in Patients with Unresectable Advanced Gastric Cancer

et al. 2017

View full text Add to dashboard Cite

PurposeBleeding is one of the most serious complications of advanced gastric cancer (AGC) and is associated with a poor prognosis. This study aimed to evaluate the clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable AGC.Materials and MethodsThis study included 106 patients with bleeding associated with gastric cancer who had undergone endoscopic hemostasis between January 2010 and December 2013. Clinical characteristics, treatment outcomes, including rates of successful endoscopic hemostasis and rebleeding, risk factors for rebleeding, and overall survival (OS) were investigated.ResultsSuccessful initial hemostasis was achieved in 83% of patients. Rebleeding occurred in 28.3% of patients within 30 days. The median OS after initial hemostasis was lower in patients with rebleeding than in those without rebleeding (2.7 and 3.9 months, respectively, P=0.02). There were no significant differences in disease status and rebleeding rates among patients with partial response or stable disease (n=4), progressive disease (n=64), and first diagnosis of disease (n=38). Univariate and multivariate analyses (P=0.038 and 0.034, respectively) revealed that transfusion of ≥5 units of RBCs was a significant risk factor for rebleeding.ConclusionsDespite favorable success rates of endoscopic hemostasis for bleeding associated with gastric cancer, the 30-day rebleeding rate was 28.3% and the median OS was significantly lower in patients with rebleeding than in those without rebleeding. Massive transfusion (≥5 units of RBCs) was the only significant risk factor for rebleeding. Patients with bleeding associated with AGC who have undergone massive transfusion should be observed closely following endoscopic hemostasis. Further research on approaches to reduce rebleeding rate and prevent death is needed.

show abstract